Mostrar el registro sencillo del ítem

dc.contributor.authorSantos-Moreno, Pedrospa
dc.contributor.authorALVIS-ZAKZUK, NELSON J.spa
dc.contributor.authorVillarreal-Peralta, Lauraspa
dc.contributor.authorCarrasquilla Sotomayor, Mariaspa
dc.contributor.authorde la Hoz Restrepo, Fernandospa
dc.contributor.authorAlvis-Guzmán, Nelsonspa
dc.date.accessioned2021-07-27T13:29:41Z
dc.date.available2021-07-27T13:29:41Z
dc.date.issued2021
dc.identifier.urihttps://hdl.handle.net/11323/8489spa
dc.description.abstractBackground: Health systems need to optimize the use of resources, especially in high-cost diseases as rheumatoid arthritis (RA). We aimed to evaluate the efficiency of using centers of excellence (CoE) as a strategy for improving RA treatment in Colombia. Methods: A cost description analysis was carried out using the standard costing technique. We estimated the costs of medical consultations, laboratories, images, and medications for RA. Categories of care standards stratified by severity were defined using the disease activity score in 28 joints (DAS28). We evaluated the impact, in terms of costs (US dollars), for providing RA clinical care for a previously described cohort using the CoE approach. Statistical analyses were performed in Microsoft Excel®, and R. Results: Expenditure on therapeutic drugs increases as the severity of RA increases. Drugs represent 53.6% of the total cost for the low disease activity (LDA) stage, 75.2% for moderate disease activity (MDA), 88.5% for severe disease activity (SDA) and 97% for SDA with biologic treatment (SDA+Biologic). Treating 968 patients would cost US$612,639 (US$487,978– 1,220,160) at baseline, per year. After a year of follow-up at the CoE, treating the same patients would cost US$388,765 (US$321,710– 708,476), which implies potential cost-savings of up to US$223,874 per year. Conclusion: The strategy of providing clinical care for RA through CoE can save US$231.3 per patient-per year. The results of our study show that CoE could greatly impact the public policies dealing with treatment of RA in Colombia. Applying the CoE model in our country would both improve health outcomes, as well as being more efficient in terms of costs.spa
dc.format.mimetypeapplication/pdfspa
dc.language.isoeng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/spa
dc.sourceClinicoEconomics and Outcomes Researchspa
dc.subjectrheumatoid arthritisspa
dc.subjecttreat to targetspa
dc.subjectcost-savingsspa
dc.subjectcost-analysisspa
dc.titleCenters of excellence implementation for treating rheumatoid arthritis in Colombia: A cost-analysisspa
dc.typeArtículo de revistaspa
dc.source.urlhttps://www.dovepress.com/centers-of-excellence-implementation-for-treating-rheumatoid-arthritis-peer-reviewed-fulltext-article-CEORspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.identifier.doihttps://doi.org/10.2147/CEOR.S308024spa
dc.identifier.instnameCorporación Universidad de la Costaspa
dc.identifier.reponameREDICUC - Repositorio CUCspa
dc.identifier.repourlhttps://repositorio.cuc.edu.co/spa
dc.relation.referencesNell VPK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology. 2004;43(7):906–914. doi:10.1093/rheumatology/keh199spa
dc.relation.referencesvan der Linden MPM, Le Cessie S, Raza K, et al. Long‐term impact of delay in assessment of patients with early arthritis. Arthritis Rheumatol. 2010;62(12):3537–3546. doi:10.1002/art.27692spa
dc.relation.referencesPuchner R, Hochreiter R, Pieringer H, Vavrovsky A. Improving patient flow of people with rheumatoid arthritis has the potential to simultaneously improve health outcomes and reduce direct costs. BMC Musculoskelet Disord. 2017;18(1):7. doi:10.1186/s12891-016-1362-7spa
dc.relation.referencesHogan DR, Stevens GA, Hosseinpoor AR, Boerma T. Monitoring universal health coverage within the Sustainable Development Goals: development and baseline data for an index of essential health services. Lancet Glob Heal. 2018;6(2):e152–68. doi:10.1016/S2214-109X(17)30472-2spa
dc.relation.referencesEvans DB, Etienne C. Health systems financing and the path to universal coverage. Bull World Health Organ. 2010;88(6):402. doi:10.2471/BLT.10.078741spa
dc.relation.referencesAmaya-Lara JL. Catastrophic expenditure due to out-of-pocket health payments and its determinants in Colombian households. Int J Equity Health. 2016;15(1):182. doi:10.1186/s12939-016-0472-zspa
dc.relation.referencesCastro-Rodríguez A, Machado-Duque ME, Gaviria-Mendoza A, Medina-Morales DA, Álvarez-vera T, Machado-Alba JE. Factors related to excessive polypharmacy (≥15 medications) in an outpatient population from Colombia. Int J Clin Pract. 2018;e13278. doi:10.1111/ijcp.13278spa
dc.relation.referencesSantos-Moreno P, Castañeda O, Garro B, Flores D, Sánchez G, Castro C. From the model of integral attention to the creation of centers of excellence in rheumatoid arthritis. Clin Rheumatol. 2015;34(S1):71–77. doi:10.1007/s10067-015-3017-8spa
dc.relation.referencesSantos-Moreno P, Galarza-Maldonado C, Caballero-Uribe CV, et al. REAL-PANLAR project for the implementation and accreditation of centers of excellence in rheumatoid arthritis throughout Latin America. JCR J Clin Rheumatol. 2015;21(4):175–180. doi:10.1097/RHU.0000000000000247spa
dc.relation.referencesSmolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2012;69:631–637. doi:10.1136/ard.2009.123919spa
dc.relation.referencesSmolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2015;1–13.spa
dc.relation.referencesCuenta de Alto Costo. Situación de la artritis reumatoide en Colombia [Internet]. 2017. ISSN: 2590–9037. Available from: https://cuentadealtocosto.org/site/download/situacion-de-la-artritis-reumatoide-en-colombia-2017/.spa
dc.relation.referencesMinisterio de Salud y Protección Social. Guía de Práctica Clínica para la detección temprana, diagnóstico y tratamiento de la artritis reumatoide. 2014.spa
dc.relation.referencesAlemao E, Al MJ, Boonen AA, et al. Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. Nurmohamed M, editor. PLoS One. 2018;13(10):e0205013. doi:10.1371/journal.pone.0205013spa
dc.relation.referencesSantos-Moreno P, Alvis-Zakzuk NJ, Villarreal-Peralta L, Carrasquilla-Sotomayor M, Paternina-Caicedo A, Alvis-Guzmán N. A comprehensive care program achieves high remission rates in rheumatoid arthritis in a middle-income setting. Experience of a Center of Excellence in Colombia. Rheumatol Int. 38(3):499–505. doi:10.1007/s00296-017-3903-2.spa
dc.relation.referencesDrummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford university press; 2015:445.spa
dc.relation.referencesRovira J, Antoñanzas F. Economic analysis of health technologies and programmes. Pharmacoeconomics. 1995;8(3):245–252. doi:10.2165/00019053-199508030-00007spa
dc.relation.referencesHjelmgren J, Berggren F, Andersson F. Health economic guidelines—similarities, differences and some implications. Value Heal. 2001;4(3):225–250. doi:10.1046/j.1524-4733.2001.43040.xspa
dc.relation.referencesLoras C, Mayor V, Fernández-Bañares F, Esteve M. Study of the standard direct costs of various techniques of advanced endoscopy. Comparison with surgical alternatives. Dig Liver Dis. 2018;50(7):689–697. doi:10.1016/j.dld.2018.03.002spa
dc.relation.referencesAmat O, Soldevila P, Aguilà S Contabilidad y gestión de costes. Profit; 2011.spa
dc.relation.referencesInstituto de Evaluación Tecnológica en Salud-IETS. Manual para la elaboración de evaluaciones económicas en salud. Bogotá - Colombia: Instituto de Evaluación Tecnológica en Salud; 2014.spa
dc.relation.referencesInstituto de Evaluación Tecnológica en Salud. Qué es el IETS. 2018.spa
dc.relation.referencesSISPRO. Sistema Integral de Información de la Protección Social.spa
dc.relation.referencesde la República B. Tasa de cambio representativa del mercado (TRM). Available from: https://www.banrep.gov.co/es/estadisticas/trm. Accessed May 17, 2021.spa
dc.relation.referencesViegas Brenol C, Mendonça Silva da Chakr R, Pamplona Bueno Andrade N, et al. Daily practice feasibility and effectiveness of treating long-standing rheumatoid arthritis to target with synthetic disease-modifying antirheumatic drugs: a prospective cohort study. Clin Rheumatol. 2015;34(10):1781–1785. doi:10.1007/s10067-015-2915-0spa
dc.relation.referencesSantos-Moreno PI, De La Hoz-valle J, Villarreal L, Palomino A, Sánchez G, Castro C. Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study. Clin Rheumatol. 2015;34(2):215–220. doi:10.1007/s10067-014-2794-9spa
dc.relation.referencesLing E, Ofer-Shiber S, Goren O, Molad Y. Outcome of patients with rheumatoid arthritis: cross-sectional study of a single-center real-world inception cohort. Isr Med Assoc J. 2013;15(12):758–762.spa
dc.relation.referencesMachado-Alba JE, Ruiz AF, Machado-Duque ME. Effectiveness of treatment with biologic- and disease-modifying antirheumatic drugs in rheumatoid arthritis patients in Colombia. Int J Clin Pract. 2016;70(6):506–511. doi:10.1111/ijcp.12809spa
dc.relation.referencesMinisterio de Trabajo. Decreto número 2552 de 2015. 2015. Available from: https://www.funcionpublica.gov.co/eva/gestornormativo/norma.php?i=67555. Accessed May 17, 2021.spa
dc.relation.referencesGamboa-Cárdenas RV, Ugarte-Gil MF, Loreto M, et al. Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort. Clin Rheumatol. 2019;38(10):2737–2746. doi:10.1007/s10067-019-04618-xspa
dc.relation.referencesHresko A, Lin T-C, Solomon DH. Medical care costs associated with rheumatoid arthritis in the US: a systematic literature review and meta-analysis. Arthritis Care Res (Hoboken). 2018;70(10):1431–1438. doi:10.1002/acr.23512spa
dc.relation.referencesBaser O, Baser E, Altinbas A, Burkan A. Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey. Health Econ Rev. 2013;3(1):5. doi:10.1186/2191-1991-3-5spa
dc.relation.referencesLakomek H-J, Krause A. “Treat-to-Target“ (T2T) aus der Sicht der stationären Rheumatologie. Z Rheumatol. 2011;70(8):656–663. doi:10.1007/s00393-011-0765-yspa
dc.relation.referencesVoshaar MJH, Nota I, Van De Laar MAFJ, Van Den Bemt BJF. Patient-centred care in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2015;29(4–5):643–663. doi:10.1016/j.berh.2015.09.007spa
dc.relation.referencesBidaut-Russell M, Gabriel SE. Adverse gastrointestinal effects of NSAIDs: consequences and costs. Best Pract Res Clin Gastroenterol. 2001;15(5):739–753. doi:10.1053/bega.2001.0232spa
dc.relation.referencesInstituto Nacional de Salud - Observatorio Nacional de Salud. Quinto Informe ONS: Carga de enfermedad por enfermedades crónicas no transmisibles y discapacidad en Colombia. (Pág. 160). Bogotá, DC: Imprenta Nacional de Colombia; 2015.spa
dc.relation.referencesLenz-alcayaga R. Análisis de costos en evaluaciones económicas en salud: aspectos introductorios. 2010;138(Supl2):88–92.spa
dc.relation.referencesBernal-Aguirre C, Carvajal-Sierra H, Alvis-Zakzuk NJ. Costos económicos de la infección respiratoria aguda en un Municipio de Colombia. Rev La Univ Ind Santander Salud. 2017;49(3):470–477.spa
dc.relation.referencesRice DP. Estimating the Cost-Of-Illness. Washington, DC: US Department of Health, Education, and Welfare, Public Health Service; 1966.spa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa


Ficheros en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

  • Artículos científicos [3120]
    Artículos de investigación publicados por miembros de la comunidad universitaria.

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 International
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International